"MAP Kinase Kinase 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 44 kDa mitogen-activated protein kinase kinase with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048370
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.200 D08.811.913.696.620.682.725.200.200 D12.644.360.440.200 D12.776.476.440.200
|
| Concept/Terms |
MAP Kinase Kinase 2- MAP Kinase Kinase 2
- Kinase Activator Kinase MEK2
- MAPK-ERK Kinase 2
- MAPK ERK Kinase 2
- MAP2K2 Protein
- MAPK Extracellular Signal-Regulated Kinase 2
- MAPK Extracellular Signal Regulated Kinase 2
- Mitogen-Activated Protein Kinase Kinase 2
- Mitogen Activated Protein Kinase Kinase 2
- MEK-2 (MAPK Extracellular Signal-Regulated Kinase 2)
- MAPK Kinase 2
- MEK2 (MAPK Extracellular Signal-Regulated Kinase 2)
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 2".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 2".
This graph shows the total number of publications written about "MAP Kinase Kinase 2" by people in this website by year, and whether "MAP Kinase Kinase 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 2" by people in Profiles.
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
-
Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 03; 567(7749):521-524.
-
Interaction of tRNA with MEK2 in pancreatic cancer cells. Sci Rep. 2016 06 15; 6:28260.
-
The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28.
-
ECM-dependent HIF induction directs trophoblast stem cell fate via LIMK1-mediated cytoskeletal rearrangement. PLoS One. 2013; 8(2):e56949.
-
RasGRP1 stimulation enhances ubiquitination and endocytosis of the sodium-chloride cotransporter. Am J Physiol Renal Physiol. 2010 Aug; 299(2):F300-9.
-
Involvement of Per-Arnt-Sim Kinase and extracellular-regulated kinases-1/2 in palmitate inhibition of insulin gene expression in pancreatic beta-cells. Diabetes. 2009 Sep; 58(9):2048-58.
-
Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation. FEBS Lett. 2005 Jul 04; 579(17):3497-502.
-
A novel mitogen-activated protein kinase is responsive to Raf and mediates growth factor specificity. Mol Cell Biol. 2001 Mar; 21(6):2235-47.
-
Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. J Immunol. 2001 Jan 01; 166(1):522-30.